MEI Pharma Inc. chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.33
Dividend & YieldN/A£ (N/A)
Beta 0.91
Market capitalization 258.43k
Operating cash flow -48.75M
ESG Scores unknown

Company description

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

Sector: - Industry:

Financial data

Financial Statements

Cashflow Statement 2019-06-30 2020-06-30 2021-06-30 2022-06-30
Change To Liabilities 8.13M 73.53M -517k 17.79M
Total Cashflows From Investing Activities 24.32M -106.29M 24.71M 6.89M
Net Borrowings
Total Cash From Financing Activities 1.39M 74.78M 3.47M 49.05M
Change To Operating Activities 455k -19.76M 22.18M 1.55M
Issuance Of Stock 1.71M 78.51M 3.53M 52.9M
Net Income -16.82M -47.17M -41.31M -54.45M
Change In Cash -3.72M 2.74M -3.79M 7.2M
Effect Of Exchange Rate
Total Cash From Operating Activities -29.42M 34.26M -31.96M -48.75M
Depreciation 80k 109k 285k 326k
Change To Account Receivables -199k -2.35M -4.72M -2.46M
Other Cashflows From Financing Activities -3.73M -3.73M -64k -3.65M
Change To Netincome -21.07M 29.9M -7.88M -11.49M
Capital Expenditures -217k -894k -708k -479k

Income Statement 2019-06-30 2020-06-30 2021-06-30 2022-06-30
Research Development 32.3M 34.06M 69.4M 85.64M
Income Before Tax -16.82M -47.17M -41.31M -54.45M
Net Income -16.82M -47.17M -41.31M -54.45M
Selling General Administrative 14.6M 16.72M 24.41M 30.54M
Gross Profit 652k 25.09M 33.39M 40.7M
Ebit -46.24M -25.7M -60.42M -75.48M
Operating Income -46.24M -25.7M -60.42M -75.48M
Interest Expense
Income Tax Expense 1k 1k 8k
Total Revenue 4.92M 27.76M 34.8M 40.7M
Cost Of Revenue 4.26M 2.67M 1.41M
Total Other Income ExpenseNet 29.43M -21.48M 19.12M 21.03M
Net Income From Continuing Ops -16.82M -47.17M -41.31M -54.45M
Net Income Applicable To Common Shares -16.82M -47.17M -41.31M -54.45M

Balance Sheet Statement 2019-06-30 2020-06-30 2021-06-30 2022-06-30
Total Liabilities 34.73M 132.67M 124.63M 125.43M
Total Stockholder Equity 47.93M 77.06M 49.47M 52.41M
Other Current Liabilities 4.96M 5.23M 4.53M 4.83M
Total Assets 82.66M 209.73M 174.1M 177.84M
Common Stock
Other Current Assets 20.42M
Retained Earnings -231.22M -278.39M -319.7M -374.16M
Treasury Stock
Cash 9.59M 12.33M 8.54M 15.74M
Total Current Liabilities 14.3M 13.76M 20.21M 24.44M
Other Stockholder Equity
Property, Plant, and Equipment 204k 1.08M 9.28M 10.71M
Total Current Assets 82.2M 208.64M 164.82M 167.13M
Net Tangible Assets 47.67M 77.06M 49.47M 52.41M
Net Receivables 5.96M 2.94M 7.58M 10.04M
Accounts Payable 4.79M 2.44M 6.36M 7.92M


Insider Transactions

Here are the insider transactions of stock shares related to MEI Pharma Inc.:

Filer Name Transaction Text Ownership Date Filer Relation Shares
GOLD DANIEL PConversion of Exercise of derivative security at price 2.52 per share.D2021-05-25Chief Executive Officer5k
DRISCOLL FREDERICK WSale at price 4.03 per share.D2021-02-23Director25k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to MEI Pharma Inc.. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on MEI Pharma Inc.

Here is the result of two systematic investment strategies applied to MEI Pharma Inc.. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on MEI Pharma Inc.

The following chart shows the equity curve of the two systematic investment strategies applied to MEI Pharma Inc.:

MEI Pharma Inc. automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 0% on the backtest period.

Performance at glance

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

0.0 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on MEI Pharma Inc.

This is the result of two momentum investment strategies applied to MEI Pharma Inc.. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on MEI Pharma Inc.

The following chart shows all the entries opened by the momentum investment system on MEI Pharma Inc.:

MEI Pharma Inc. momentum entries
  • The first momentum investment strategy would give 0% of return on MEI Pharma Inc.. That represents 0.0£ of latent gain with 0.0£ of employed capital.
  • The second momentum investment strategy would give 0% of return on MEI Pharma Inc.. That represents 0.0£ of latent gain with 0.0£ of employed capital.
Performance at glance (1Q Momentum)

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

-0.0 %
Performance at glance (2Q Momentum)

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

-0.0 %

Momentum equity curve on MEI Pharma Inc.

The following chart shows the equity curve of the two momentum strategies applied to MEI Pharma Inc.:

MEI Pharma Inc. momentum equity

Note: the dividends potentially given by MEI Pharma Inc. are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on MEI Pharma Inc.

The following chart shows the employed capital evolution of the two momentum strategies on MEI Pharma Inc. since the beginning:

MEI Pharma Inc.

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250£, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000£.


Buy the dip strategy result on MEI Pharma Inc.

Buy the dip entry openings on MEI Pharma Inc.

MEI Pharma Inc.

The performance achieved by the robo-advisor on MEI Pharma Inc. is 0%. That represents 0.0$ of latent gain with 0.0£ of employed capital. The following chart shows MEI Pharma Inc. stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of MEI Pharma Inc., and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

-0.0 %

Equity curve of the strategy applied to MEI Pharma Inc.

The following chart shows the result of the investment strategy applied to MEI Pharma Inc.:

MEI Pharma Inc.

Note: the dividends potentially given by MEI Pharma Inc. are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on MEI Pharma Inc.

The following chart shows the employed capital evolution since the beginning of the investment strategy on MEI Pharma Inc.:

MEI Pharma Inc.

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on MEI Pharma Inc.

In this section, I will compare the three previous investment strategies applied to MEI Pharma Inc..

Equity curve comparison on MEI Pharma Inc.

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

MEI Pharma Inc. investment strategy comparison

Employed capital comparison on MEI Pharma Inc.

MEI Pharma Inc. investment comparison

Performance comparison on MEI Pharma Inc.

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 0% 0.0£ 0.0£ 0.0%
Momentum 1 quarter 0% 0.0£ 0.0£ -0.0%
Momentum 2 quarters 0% 0.0£ 0.0£ -0.0%
Non-directional 0% 0.0£ 0.0£ -0.0%
Annualized return comparison

Automatic investment

0.0 %

Momentum 1Q

-0.0 %

Momentum 2Q

-0.0 %

Non-directional

-0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with MEI Pharma Inc.:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between MEI Pharma Inc. and the other stocks. There may be false positives or some missing correlated stocks. If the price of MEI Pharma Inc. does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name MEI Pharma Inc.
Country United States
City San Diego
Address 11455 El Camino Real
Phone 858 369 7100
Website www.meipharma.com
FullTime employees 102
Industry
Sector
Exchange XLON
Ticker 0JW9.XLON
Market www.londonstockexchange.com

MEI Pharma Inc. ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown